Of IDD, 7 (23%) used loperamide or activated carbon, and 3 (10%) used oral rehydration solution, versus 10 (34%) and 1 (3%) of 29 controls with diarrhea, respectively (not statistically different). Of NIDD, 9 (28%) used loperamide or
activated carbon, and 1 (3%) used oral rehydration solution, versus 12 (34%) and 1 (3%) of 35 controls with diarrhea, respectively this website (not statistically different). As to the use of other medication (antibiotics, antipyretics, and anti-inflammatory drugs) and doctor consultations, both IDD and NIDD were comparable to their controls. This is the first prospective study evaluating whether medication-dependent travelers with diabetes to developing countries are at increased risk for developing symptomatic infectious diseases. Although we hypothesized that they would have symptoms more often and longer than non-immune-suppressed travelers
without diabetes, no differences in travel-related diarrhea, vomiting, fever, cough, Venetoclax or rhinitis were found. The NIDD had signs of skin infection more often than controls, unrelated to travel. A higher incidence rate and burden of non-travel-related signs of skin infection among persons with diabetes have been reported before, irrespective of insulin use.9,16 Why we found increased risk for skin infection only among NIDD and not IDD may reflect differences in age, exposure, or unknown co-morbidity, such as preexisting skin disease, carriage of Staphylococcus aureus, peripheral neuropathy, or microvascular disease.9,17 Because bacterial skin infection can be life-threatening, especially for people with diabetes, stand-by antibiotics for this may be useful for areas where the availability of proper treatment is Bay 11-7085 poor. This needs further investigation. Before travel, disease burden of cough seemed
to be lower among IDD than controls. This coincided with a higher prevalence of asthma or chronic obstructive pulmonary disease among the controls, although the difference was not statistically significant (p > 0.05). Before travel, outcome measures for diarrhea and vomiting were higher among NIDD than controls. The increased diarrhea might be explained by medication, as the oral anti-diabetic metformin is known for such gastrointestinal side effects.18 Also, diarrhea has been associated with metabolic dysregulation. A retrospective population-based survey linked poorer levels of self-reported glycemic control with a higher prevalence rate of non-travel-related diarrhea.19 Our study design had distinctive strengths. Structurally specified data were obtained prospectively and on a daily basis. Data collection started before departure (median 15 days) to gain insight into preexisting symptoms. It continued until 2 weeks after return from travel to encompass incubation periods of the most (acute) travel-related infectious diseases.